Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
- PMID: 34099192
- PMCID: PMC8176771
- DOI: 10.1016/j.jacl.2021.02.002
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
Comment in
-
Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia.J Clin Lipidol. 2021 Mar-Apr;15(2):381-382. doi: 10.1016/j.jacl.2021.02.003. J Clin Lipidol. 2021. PMID: 34099193 Free PMC article. No abstract available.
Comment on
-
Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia.J Clin Lipidol. 2020 Nov-Dec;14(6):751-755. doi: 10.1016/j.jacl.2020.09.002. Epub 2020 Sep 15. J Clin Lipidol. 2020. PMID: 32988799 Free PMC article.
References
-
- Taylan C., Driemeyer J., Schmitt C.P. Cardiovascular outcome of pediatric patients with bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis. Am J Cardiol. 2020;136:38–48. - PubMed
-
- Cuchel M., Bruckert E., Ginsberg H.N. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146–2157. - PMC - PubMed
-
- Sjouke B., Yahya R., Tanck M.W.T. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. J Clin Lipidol. 2017;11(2):507–514. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
